To the full analysis
Incyte stock: growth
INCYIncyte reported $5.14B in revenue for fiscal 2025, up 21.2% on the prior year, up 14% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
31.7%
per year from 2006 to 2025, per share 25.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 14.0% | 21.2% | 31.7% |
| Revenue per share | 16.6% | 20.2% | 25.9% |
| Earnings | no data | 69.6% | no data |
| Earnings per share | no data | 66.6% | no data |
| Free cash flow | no data | 36.5% | no data |
| Free cash flow per share | no data | 35.3% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $27.64M | −$74.17M | −$51.94M |
| 2007 | $34.44M | −$86.88M | −$93.85M |
| 2008 | $3.92M | −$178.92M | −$141.56M |
| 2009 | $9.27M | −$211.87M | $11.97M |
| 2010 | $169.88M | −$31.85M | $93.83M |
| 2011 | $94.46M | −$186.54M | −$165.51M |
| 2012 | $297.06M | −$44.32M | −$97.67M |
| 2013 | $354.95M | −$83.15M | $4.91M |
| 2014 | $511.5M | −$48.48M | −$1.89M |
| 2015 | $753.75M | $6.53M | $60.53M |
| 2016 | $1.11B | $104.22M | $184.48M |
| 2017 | $1.54B | −$313.14M | −$204.01M |
| 2018 | $1.88B | $109.49M | $262.74M |
| 2019 | $2.16B | $446.91M | $632.59M |
| 2020 | $2.67B | −$295.7M | −$311.98M |
| 2021 | $2.99B | $948.58M | $568.48M |
| 2022 | $3.39B | $340.66M | $892.11M |
| 2023 | $3.7B | $597.6M | $464M |
| 2024 | $4.24B | $32.62M | $249.07M |
| 2025 | $5.14B | $1.29B | $1.35B |
Revenue by segment
How Incyte Corporation makes its money and how that has shifted. Names are as the company reports them.
- J A K A F I69%
- Opzelura13%
- Milestone And Contract Revenue3%
- Olumiant Royalty3%
- M I N J U V I3%
- I C L U.S. I G3%
- Other7%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| J A K A F I | $3.21B | $3.55B | 69.1% |
| Opzelura | $508.29M | $678.46M | 13.2% |
| Milestone And Contract Revenue | $43M | $150M | 2.9% |
| Olumiant Royalty | $135.57M | $144.6M | 2.8% |
| M I N J U V I | $119.24M | $144.58M | 2.8% |
| I C L U.S. I G | $114.32M | $134.07M | 2.6% |
| Other | $109.85M | $339.29M | 6.6% |
| Total revenue | $4.24B | $5.14B | 100% |
Revenue by region
Where Incyte Corporation generates its revenue.
- U [S]93%
- Europe6%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| U [S] | $4B | $4.8B | 93.4% |
| Europe | $260.4M | $323.73M | 6.3% |
| Total revenue | $4.24B | $5.14B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.